Development
Novartis AG
NVS
$118.13
$1.291.10%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 11.42B | 11.78B | 9.28B | 12.95B | 10.58B |
| Total Other Revenue | 353.00M | 310.00M | 302.00M | 255.00M | 390.00M |
| Total Revenue | 11.78B | 12.09B | 9.58B | 13.21B | 10.97B |
| Cost of Revenue | 2.99B | 3.09B | 2.12B | 3.83B | 2.76B |
| Gross Profit | 8.79B | 9.00B | 7.47B | 9.38B | 8.21B |
| SG&A Expenses | 3.44B | 3.09B | 2.55B | 3.40B | 3.13B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 83.00M | 104.00M | 90.00M | 221.00M | -1.26B |
| Total Operating Expenses | 8.79B | 8.64B | 6.71B | 9.88B | 6.10B |
| Operating Income | 2.99B | 3.45B | 2.87B | 3.33B | 4.87B |
| Income Before Tax | 2.38B | 1.55B | 2.45B | 2.74B | 1.57B |
| Income Tax Expenses | -261.00M | 39.00M | 327.00M | 446.00M | 254.00M |
| Earnings from Continuing Operations | 2.64B | 1.51B | 2.13B | 2.29B | 1.32B |
| Earnings from Discontinued Operations | 5.84B | 250.00M | -- | -- | 151.00M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | -2.00M | -1.00M | -1.00M | -- |
| Net Income | 8.48B | 1.76B | 2.32B | 2.29B | 1.47B |
| EBIT | 2.99B | 3.45B | 2.87B | 3.33B | 4.87B |
| EBITDA | 4.07B | 4.70B | 4.00B | 4.75B | 6.08B |
| EPS Basic | 4.14 | 0.85 | 1.11 | 1.09 | 0.69 |
| Normalized Basic EPS | 0.88 | 0.99 | 0.84 | 0.96 | 1.36 |
| EPS Diluted | 4.11 | 0.85 | 1.11 | 1.08 | 0.69 |
| Normalized Diluted EPS | 0.88 | 0.98 | 0.83 | 0.95 | 1.35 |
| Average Basic Shares Outstanding | 2.05B | 2.06B | 2.10B | 2.11B | 2.18B |
| Average Diluted Shares Outstanding | 2.07B | 2.08B | 2.11B | 2.12B | 2.20B |
| Dividend Per Share | 3.92 | -- | -- | -- | 3.46 |
| Payout Ratio | 0.00% | -- | 157.41% | 316.40% | 107.92% |